OxThera is built on a highly-experienced and committed team and strong network in oxaluria research, rare disease drug development and anaerobic bacterial manufacturing.

Leadership Team and Strategic Advisor

Matthew Gantz
Chief Executive Officer

Mats-Olof Wallin
Chief Financial Officer

Bastian Dehmel
Chief Medical Officer

Elisabeth Lindner
Strategic Advisor

Matthew Gantz, Chief Executive Officer

Born 1965. CEO since 2017.
Education: BA from Princeton University. MBA from Harvard
Other current assignments: Member of the board of
directors of Swedish Orphan Biovitrum AB and Marine Corps
Scholarship Foundation.
Previous assignments (last five years): EVP (US) at BTG plc.
Member of the board of directors of Life Sciences PA.
Shareholding in the Company: Matthew Gantz holds 10,618,294
Class A Options in the Company.

Mats-Olof Wallin, Chief Financial Officer

Born 1951. Deputy CEO since 2020 and CFO since 2020.
Education: BSc, Uppsala University
Other current assignments: Deputy board member and CEO
of OxThera Intellectual Property AB. Chairman of the board of
directors and CEO of Mowin Konsult AB.
Previous assignments (last five years): CFO of Karo Pharma AB
and Sobi AB.
Shareholding in the Company: Mats-Olof Wallin holds no
shares in the Company.

Bastian Dehmel, Chief Medical Officer

Born 1970. CMO since 2017.
Education: Staatsexamen from Freie Universitaet Berlin.
Doctoral Degree from the Humboldt University, Charite.
Other current assignments: -
Previous assignments (last five years): -
Shareholding in the Company: Bastian Dehmel holds 3,981,860
Class A Options in the Company.

Elisabeth Lindner, Strategic Advisor

Elisabeth Lindner is a Member of the Royal Swedish Academy of Engineering Sciences and has long-term senior management experience from Pharmacia Corporation, Octapharma, and Diamyd Medical among others. Mrs Lindner holds a MSc from the Royal Institute of Technology and an MBA from Uppsala University.